
Gilead Sciences Inc
NASDAQ:GILD

US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
Banking
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
Technology
|
US |
![]() |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
US |
![]() |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
US |
![]() |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
US |
![]() |
Visa Inc
NYSE:V
|
Technology
|
CN |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
US |
![]() |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
Beverages
|
US |
![]() |
Walmart Inc
NYSE:WMT
|
Retail
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
61.5639
116.04
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
![]() |
Johnson & Johnson
NYSE:JNJ
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
US |
![]() |
UnitedHealth Group Inc
NYSE:UNH
|
US |
![]() |
Exxon Mobil Corp
NYSE:XOM
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
US |
![]() |
Nike Inc
NYSE:NKE
|
US |
![]() |
Visa Inc
NYSE:V
|
US |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
![]() |
3M Co
NYSE:MMM
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
US |
![]() |
Walmart Inc
NYSE:WMT
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.

Intrinsic Value
The intrinsic value of one
GILD
stock under the Base Case scenario is
102.99
USD.
Compared to the current market price of 116.04 USD,
Gilead Sciences Inc
is
Overvalued by 11%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Gilead Sciences Inc
Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.

Valuation History
Historical valuation for GILD cannot be conducted due to limitations such as insufficient data or other constraints.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:

Gilead’s heavy reliance on its HIV portfolio could hinder long-term growth if new competitive therapies and emerging generics erode market share faster than forecast, putting pressure on revenues and margins.
Despite significant investments in oncology, some of Gilead’s pipeline candidates have faced setbacks, raising doubts about the company’s ability to diversify beyond its core antivirals and deliver strong returns on high-cost acquisitions.
Stagnating sales in the hepatitis C segment, amplified by intensified competition and price pressures, may challenge management’s efforts to sustain overall top-line growth and maintain investor confidence.
Gilead’s robust HIV franchise, led by Biktarvy, continues to post solid growth and enjoy strong patent protection, providing a stable revenue base and healthy cash flow to fund R&D and strategic acquisitions.
The company’s expanding oncology pipeline, bolstered by acquisitions like Kite Pharma and Immunomedics, offers potential for long-term diversification as novel cell and targeted therapies begin to gain traction in large cancer markets.
Gilead’s consistent free cash flow generation affords management the flexibility to pursue strategic partnerships and invest aggressively in innovative therapeutic areas, positioning the firm ahead of rivals seeking to build similar franchises.

Revenue & Expenses Breakdown
Gilead Sciences Inc
Balance Sheet Decomposition
Gilead Sciences Inc
Current Assets | 18B |
Cash & Short-Term Investments | 10B |
Receivables | 4.4B |
Other Current Assets | 3.6B |
Non-Current Assets | 41B |
PP&E | 5.4B |
Intangibles | 28.3B |
Other Non-Current Assets | 7.3B |
Current Liabilities | 12B |
Other Current Liabilities | 12B |
Non-Current Liabilities | 27.7B |
Other Non-Current Liabilities | 27.7B |
Free Cash Flow Analysis
Gilead Sciences Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Gilead Sciences Inc
Revenue
|
28.8B
USD
|
Cost of Revenue
|
-6.3B
USD
|
Gross Profit
|
22.5B
USD
|
Operating Expenses
|
-11.6B
USD
|
Operating Income
|
10.9B
USD
|
Other Expenses
|
-10.4B
USD
|
Net Income
|
480m
USD
|
GILD Profitability Score
Profitability Due Diligence
Gilead Sciences Inc's profitability score is 62/100. The higher the profitability score, the more profitable the company is.

Score
Gilead Sciences Inc's profitability score is 62/100. The higher the profitability score, the more profitable the company is.
GILD Solvency Score
Solvency Due Diligence
Gilead Sciences Inc's solvency score is 60/100. The higher the solvency score, the more solvent the company is.

Score
Gilead Sciences Inc's solvency score is 60/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
GILD Price Targets Summary
Gilead Sciences Inc
According to Wall Street analysts, the average 1-year price target for
GILD
is 109.81 USD
with a low forecast of 82.82 USD and a high forecast of 136.5 USD.
Dividends
Current shareholder yield for GILD is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
GILD
stock under the Base Case scenario is
102.99
USD.
Compared to the current market price of 116.04 USD,
Gilead Sciences Inc
is
Overvalued by 11%.